Palonosetron — Discount Pricing

Other medications in Oncology Support

• Aprepitant
• Darbepoetin Alfa
• Fosaprepitant
• Ondansetron ODT

About Palonosetron

Facing the challenging side effects of certain medical treatments, like chemotherapy, can be daunting. Palonosetron offers a powerful solution to combat severe nausea and vomiting, helping you maintain a better quality of life. At TheDrugClub, we believe essential medications should be accessible, and we're here to help our members find significant savings on prescriptions like palonosetron.

Palonosetron is a highly effective medication primarily used to prevent and treat nausea and vomiting, particularly those induced by chemotherapy (CINV) and occurring after surgery (PONV). These conditions can be debilitating, often leading to dehydration, malnutrition, and a significant decrease in a patient's overall well-being. By proactively managing these side effects, palonosetron helps patients adhere to their treatment plans and recover more comfortably.

So, how does this powerful antiemetic work? Palonosetron belongs to a class of drugs known as 5-HT3 receptor antagonists. It functions by blocking the action of serotonin, a natural substance in the body that can trigger nausea and vomiting. Serotonin acts on specific receptors in the gastrointestinal tract and the brain's vomiting center. By binding to and blocking these 5-HT3 receptors, palonosetron effectively prevents serotonin from initiating the vomiting reflex, providing sustained relief for up to several days after a single dose.

When considering the typical costs, palonosetron is often a specialty medication, frequently administered intravenously in a clinical setting, though oral forms are also available. As a potent, often brand-name drug, its price without insurance or a robust discount program can be substantial. A single dose can range from several hundred to over a thousand dollars, depending on the dosage, formulation, and

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Palonosetron is approved for (FDA label)

Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride is recommended even where the incidence of postoperative nausea and/or vomiting is low.

Source: Read the full FDA label on DailyMed. Label effective date: August 25, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Palonosetron (FDA label)

Palonosetron hydrochloride injection is sterile, clear, and colorless solution: • 0.25 mg palonosetron in 5 mL (0.05 mg/mL) in a single-dose vial Injection: 0.25 mg palonosetron in 5mL (0.05 mg/mL) in a single-dose vial (3)

Source: FDA prescribing information (DailyMed). Set ID: ee6f6f94-1ca7-481e-9909-b19ae64e80c2. SPL document ID: 59e26e01-70a8-ce59-e063-6294a90a45c8. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Palonosetron (FDA label)

Serious or otherwise clinically significant adverse reactions reported in other sections of labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Serotonin Syndrome [see Warnings and Precautions ( 5.2 )] Most common adverse reactions in chemotherapy-induced nausea and vomiting in adults (≥5%) are: headache and constipation ( 6.1). postoperative nausea and vomiting (≥2%) are: QT prolongation, bradycardia, headache, and constipation ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Dr.

Source: FDA prescribing information (DailyMed). Set ID: ee6f6f94-1ca7-481e-9909-b19ae64e80c2. SPL document ID: 59e26e01-70a8-ce59-e063-6294a90a45c8. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Palonosetron (FDA label)

Palonosetron hydrochloride is contraindicated in patients known to have hypersensitivity to palonosetron [see Warnings and Precautions ( 5.1 )] Hypersensitivity to palonosetron or any of its components (4)

Source: FDA prescribing information (DailyMed). Set ID: ee6f6f94-1ca7-481e-9909-b19ae64e80c2. SPL document ID: 59e26e01-70a8-ce59-e063-6294a90a45c8. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Palonosetron (FDA label)

Hypersensitivity reactions, including anaphylaxis and anaphylactic shock: reported in patients with or without known hypersensitivity to other selective 5-HT 3 receptor antagonists. If symptoms occur, discontinue palonosetron hydrochloride and initiate appropriate medical treatment. ( 5.1) Serotonin syndrome : reported with 5-HT 3 receptor antagonists alone, but particularly with concomitant use of serotonergic drugs ( 5.2 , 7.1 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported with administration of palonosetron hydrochloride injection [see Adverse Reactions ( 6.2) ]. These reactions occurred in patients with or without known hypersensitivity to other 5-HT 3 receptor antagonists. If hypersensitivity reactions occur, discontinue palonosetron hydrochloride injection and initiate appropriate medical treatment. Do not reinitiate palonosetron hydrochloride injection in patients who have previously experienced symptoms of hypersensitivity [see Contraindications ( 4) ]. 5.2 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists.

Source: FDA prescribing information (DailyMed). Set ID: ee6f6f94-1ca7-481e-9909-b19ae64e80c2. SPL document ID: 59e26e01-70a8-ce59-e063-6294a90a45c8. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Palonosetron (FDA label)

Serotonergic Drugs : Monitor for serotonin syndrome; if symptoms occur, discontinue palonosetron hydrochloride and initiate supportive treatment ( 7.1 ). 7.1 Serotonergic Drugs Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT 3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRI S ). Monitor for the emergence of serotonin syndrome. If symptoms occur, discontinue palonosetron hydrochloride and initiate supportive treatment [see Warnings and Precautions ( 5.2 )]

Source: FDA prescribing information (DailyMed). Set ID: ee6f6f94-1ca7-481e-9909-b19ae64e80c2. SPL document ID: 59e26e01-70a8-ce59-e063-6294a90a45c8. Label effective date: August 25, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.